PURPOSE: PET/CT with (68)Ga-labelled [DOTA(0),Tyr(3)]-octreotide ((68)Ga-DOTA-TOC PET/CT) is a routinely used imaging modality for neuroendocrine tumours expressing somatostatin receptors (SSTR). Recent studies have shown SSTR expression in head and neck squamous cell carcinoma, albeit lower than in highly differentiated neuroendocrine tumours. We sought to determine whether nasopharyngeal carcinoma (NPC) positive for Epstein-Barr virus (EBV), a rare subtype of head and neck cancer, shows increased (68)Ga-DOTA-TOC uptake indicating expression of SSTR. METHODS: Five patients with untreated, histologically proven EBV-positive NPC were referred for (68)Ga-DOTA-TOC PET/CT. Tracer uptake in tumour lesions was assessed visually and semiquantitatively measuring maximum standardized uptake values (SUVmax) and tumour to background ratios. RESULTS: Increased tumour-specific uptake was detected in all five patients with a median SUVmax of 10.6 (range 3.6 - 17.1) in the primary tumour and 13.2 (range 6.1 - 14.5) in cervical lymph node metastases. CONCLUSION: (68)Ga-DOTA-TOC PET/CT demonstrated tracer uptake in EBV-positive NPC comparable to that in highly differentiated neuroendocrine tumours. This observation is consistent with increased SSTR expression in EBV-positive NPC and may open new diagnostic and therapeutic windows in NPC.
PURPOSE: PET/CT with (68)Ga-labelled [DOTA(0),Tyr(3)]-octreotide ((68)Ga-DOTA-TOC PET/CT) is a routinely used imaging modality for neuroendocrine tumours expressing somatostatin receptors (SSTR). Recent studies have shown SSTR expression in head and neck squamous cell carcinoma, albeit lower than in highly differentiated neuroendocrine tumours. We sought to determine whether nasopharyngeal carcinoma (NPC) positive for Epstein-Barr virus (EBV), a rare subtype of head and neck cancer, shows increased (68)Ga-DOTA-TOC uptake indicating expression of SSTR. METHODS: Five patients with untreated, histologically proven EBV-positive NPC were referred for (68)Ga-DOTA-TOC PET/CT. Tracer uptake in tumour lesions was assessed visually and semiquantitatively measuring maximum standardized uptake values (SUVmax) and tumour to background ratios. RESULTS: Increased tumour-specific uptake was detected in all five patients with a median SUVmax of 10.6 (range 3.6 - 17.1) in the primary tumour and 13.2 (range 6.1 - 14.5) in cervical lymph node metastases. CONCLUSION: (68)Ga-DOTA-TOC PET/CT demonstrated tracer uptake in EBV-positive NPC comparable to that in highly differentiated neuroendocrine tumours. This observation is consistent with increased SSTR expression in EBV-positive NPC and may open new diagnostic and therapeutic windows in NPC.
Authors: V H Schartinger; C Falkeis; K Laimer; G M Sprinzl; H Riechelmann; M Rasse; I Virgolini; J Dudás Journal: J Laryngol Otol Date: 2012-10-11 Impact factor: 1.469
Authors: Michael Gabriel; Clemens Decristoforo; Dorota Kendler; Georg Dobrozemsky; Dirk Heute; Christian Uprimny; Peter Kovacs; Elisabeth Von Guggenberg; Reto Bale; Irene J Virgolini Journal: J Nucl Med Date: 2007-04 Impact factor: 10.057
Authors: Volker H Schartinger; József Dudás; Clemens Decristoforo; Christoph Url; Johannes Schnabl; Georg Göbel; Irene J Virgolini; Herbert Riechelmann; Michael Rasse; Dietmar Waitz; Daniel Putzer Journal: Eur J Nucl Med Mol Imaging Date: 2013-05-18 Impact factor: 9.236
Authors: Kwok Seng Loh; Beatrice Waser; L K S Tan; Run Sheng Ruan; Edouard Stauffer; Jean Claude Reubi Journal: Virchows Arch Date: 2002-08-02 Impact factor: 4.064
Authors: Clemens Decristoforo; Roger Knopp; Elisabeth von Guggenberg; Marco Rupprich; Thorsten Dreger; Andre Hess; Irene Virgolini; Roland Haubner Journal: Nucl Med Commun Date: 2007-11 Impact factor: 1.690
Authors: M Gabriel; U Andergassen; D Putzer; A Kroiss; D Waitz; E Von Guggenberg; D Kendler; I J Virgolini Journal: Q J Nucl Med Mol Imaging Date: 2010-02 Impact factor: 2.346
Authors: Ingo Janssen; Elise M Blanchet; Karen Adams; Clara C Chen; Corina M Millo; Peter Herscovitch; David Taieb; Electron Kebebew; Hendrik Lehnert; Antonio T Fojo; Karel Pacak Journal: Clin Cancer Res Date: 2015-04-14 Impact factor: 12.531
Authors: M Unterrainer; C Eze; H Ilhan; S Marschner; O Roengvoraphoj; N S Schmidt-Hegemann; F Walter; W G Kunz; P Munck Af Rosenschöld; R Jeraj; N L Albert; A L Grosu; M Niyazi; P Bartenstein; C Belka Journal: Radiat Oncol Date: 2020-04-21 Impact factor: 3.481
Authors: Matt Lechner; Volker H Schartinger; Christopher D Steele; Wen Long Nei; Marc Lucas Ooft; Liesa-Marie Schreiber; Christodoulos P Pipinikas; Grace Tin-Yun Chung; Yuk Yu Chan; Feng Wu; Ka-Fai To; Chi Man Tsang; Wayne Pearce; Daniele Morelli; Martin Philpott; Liam Masterson; Reshma Nibhani; Graham Wells; Christopher G Bell; Julia Koller; Susanne Delecluse; Yim Ling Yip; Jacklyn Liu; Cillian T Forde; Martin D Forster; Amrita Jay; József Dudás; Annika Krapp; Simon Wan; Christian Uprimny; Susanne Sprung; Johannes Haybaeck; Tim R Fenton; Kerry Chester; Christina Thirlwell; Gary Royle; Teresa Marafioti; Rajeev Gupta; Sagung Rai Indrasari; Camelia Herdini; Mohd Afiq Mohd Slim; I Indrawati; Liam Sutton; Renske Fles; Bing Tan; Joe Yeong; Amit Jain; Shuting Han; Haitao Wang; Kelvin S H Loke; Wan He; Ruilian Xu; Hongtao Jin; Zhiqiang Cheng; David Howard; Peter H Hwang; Quynh-Thu Le; Joshua K Tay; Robert B West; Sai Wah Tsao; Tim Meyer; Herbert Riechelmann; Udo Oppermann; Henri-Jacques Delecluse; Stefan M Willems; Melvin L K Chua; Pierre Busson; Kwok Wai Lo; Guido Wollmann; Nischalan Pillay; Bart Vanhaesebroeck; Valerie J Lund Journal: Nat Commun Date: 2021-01-05 Impact factor: 14.919
Authors: Oscar Emanuel; Jacklyn Liu; Volker H Schartinger; Wen Long Nei; Yuk Yu Chan; Chi Man Tsang; Herbert Riechelmann; Liam Masterson; Johannes Haybaeck; Udo Oppermann; Stefan M Willems; Marc L Ooft; Guido Wollmann; David Howard; Bart Vanhaesebroeck; Valerie J Lund; Gary Royle; Melvin L K Chua; Kwok Wai Lo; Pierre Busson; Matt Lechner Journal: Cancers (Basel) Date: 2021-09-30 Impact factor: 6.639